FLI1 and alveolar rhabdomyosarcoma: We did not observe a similar increase in adavosertib IC50 dose or CCNE2 mRNA expression in A673 (ES, EWSR1-FLI1+) and RH41 (alveolar rhabdomyosarcoma, PAX3-FOXO1+) cells upon CCNE1 KD (Supplemental Figure 3, A–F).